Alimenté par : Claudia (ADFI Alsace), Gaëlle (ADFI), Isabelle, Maïlé Onfray

Cet outil s'appuie sur PubMind

Un accès direct à la littérature scientifique via la base PubMed permettant de faciliter la veille sur les enjeux complexes de la santé mentale et du fait religieux : de la neuroscience des croyances à l'étude des abus spirituels, en passant par la prise en charge des traumatismes et des processus de déconversion.

Dernière synchronisation le 23/06/2026

Thérapies de Conversion

Pratiques visant à modifier l'orientation sexuelle ou l'identité de genre, illégales en France depuis la loi n°2022-92, et leurs effets psychologiques documentés.

500 articles disponibles

conversion therapy
sexual orientation change effort
SOCE harm
gender identity conversion
reparative therapy mental health
ex-gay therapy
conversion practice religious

Multidisciplinary management of surgery and postoperative recurrence in stage IV gallbladder cancer following conversion therapy: a case report.

A 61-year-old female patient presented with a 10-day history of right upper abdominal pain and was subsequently diagnosed with stage IV gallbladder cancer based on preoperative imaging and pathologica…

Thérapies de Conversion
Cheng, J., Li, X., Ren, C., Yu, S., Huang, H., Zhou, S., & Dai, J. (2025). Multidisciplinary management of surgery and postoperative recurrence in stage IV gallbladder cancer following conversion therapy: a case report.. Front Oncol, 15, 1749491. https://doi.org/10.3389/fonc.2025.1749491
01/01/2025 Lire →

Exploring Social and Structural Determinants of Substance Use Among Sexual and Gender Minority Adults in the United States.

PurposeTo identify key social and structural factors associated with hazardous alcohol and problematic drug use among sexual and gender minority (SGM) adults.MethodsWe conducted a cross-sectional seco…

Thérapies de Conversion
Zhang, C., Tang, Y., Kniffen, W., & Liu, Y. (2025). Exploring Social and Structural Determinants of Substance Use Among Sexual and Gender Minority Adults in the United States.. J Int Assoc Provid AIDS Care, 24, 23259582251409855. https://doi.org/10.1177/23259582251409855
01/01/2025 Lire →

Evaluation of Combined Lipiodol and Epirubicin-Loaded Drug-Eluting Bead Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.

PURPOSE: To evaluate the short-term clinical efficacy, side effects and risk factors affecting the clinical effectiveness of the combination of lipidol and epirubicin-loaded drug-eluting bead transart…

Thérapies de Conversion
Song, D., Feng, X., Zhou, Y., Cai, Y., & Xue, T. (2025). Evaluation of Combined Lipiodol and Epirubicin-Loaded Drug-Eluting Bead Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.. J Hepatocell Carcinoma, 12, 2723-2733. https://doi.org/10.2147/JHC.S565056
01/01/2025 Lire →

ASO Author Reflections: Can Conversion Therapy be an Option for Advanced Esophageal Cancer with Distant Metastases?

Thérapies de Conversion
Tsuji, T., Matsuda, S., Sato, Y., Tanaka, K., Sasaki, K., Watanabe, M., Hamai, Y., Nasu, M., Saze, Z., Nakashima, Y., Nomura, M., Yamamoto, S., Booka, E., Ishiyama, K., Bamba, T., Sakanaka, K., Tsushima, T., Takeuchi, H., Kato, K., & Kawakubo, H. (2025). ASO Author Reflections: Can Conversion Therapy be an Option for Advanced Esophageal Cancer with Distant Metastases?. Ann Surg Oncol, 32(1), 325-326. https://doi.org/10.1245/s10434-024-16310-9
01/01/2025 Lire →

Chemotherapy alone versus chemotherapy plus targeted therapy as adjuvant therapy for initially unresectable colorectal cancer liver metastases: a multicenter cohort study.

BACKGROUND: There is no consensus on the adjuvant treatment regimen for patients with colorectal cancer liver metastasis (CRLM) who have achieved successful conversion after surgery. This study aimed …

Thérapies de Conversion
Chang, W., Zhou, S., Guan, X., Xu, D., Liu, Y., Tang, W., Lv, Y., Qin, X., Liang, F., Wang, X., Ren, L., Fan, J., Wei, Y., Wang, X., & Xu, J. (2025). Chemotherapy alone versus chemotherapy plus targeted therapy as adjuvant therapy for initially unresectable colorectal cancer liver metastases: a multicenter cohort study.. Gastroenterol Rep (Oxf), 13, goaf098. https://doi.org/10.1093/gastro/goaf098
01/01/2025 Lire →

Development and validation of a prognostic nomogram for unresectable pancreatic ductal adenocarcinoma with synchronous liver metastases: a study based on the SEER database and an external cohort.

BACKGROUND: Pancreatic ductal adenocarcinoma with synchronous liver metastases (PDACLM) represents a highly aggressive malignancy with limited treatment options and poor prognosis. While conversion th…

Thérapies de Conversion
Huan, L., He, Q., Cao, Y., Liu, C., & Li, Y. (2025). Development and validation of a prognostic nomogram for unresectable pancreatic ductal adenocarcinoma with synchronous liver metastases: a study based on the SEER database and an external cohort.. Front Oncol, 15, 1636715. https://doi.org/10.3389/fonc.2025.1636715
01/01/2025 Lire →

Predictors of recurrence after conversion therapy in unresectable hepatocellular carcinoma treated with HAIC, bevacizumab, and sintilimab.

BACKGROUND: Conversion therapy with hepatic arterial infusion chemotherapy (HAIC) combined with bevacizumab and sintilimab has shown promise for unresectable hepatocellular carcinoma (uHCC). However, …

Thérapies de Conversion
Liu, C. F., Zhao, X. H., Zhu, S. B., Yu, H. P., Xing, W. G., & Li, H. K. (2025). Predictors of recurrence after conversion therapy in unresectable hepatocellular carcinoma treated with HAIC, bevacizumab, and sintilimab.. Front Immunol, 16, 1644570. https://doi.org/10.3389/fimmu.2025.1644570
01/01/2025 Lire →

Postoperative hepatitis B virus reactivation and its impact on survival in HBV-related hepatocellular carcinoma patients undergoing conversion therapy with interventional therapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors.

OBJECTIVE: This study aimed to investigate hepatitis B virus (HBV) reactivation and its impact on postoperative survival in patients with HBV-related hepatocellular carcinoma (HCC) who underwent conve…

Thérapies de Conversion
Xu, S., Pang, Q., Wei, M., Liu, D., Yuan, D., Bai, T., Wang, X., Tang, Z., & Wu, F. (2025). Postoperative hepatitis B virus reactivation and its impact on survival in HBV-related hepatocellular carcinoma patients undergoing conversion therapy with interventional therapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors.. Front Cell Infect Microbiol, 15, 1598193. https://doi.org/10.3389/fcimb.2025.1598193
01/01/2025 Lire →

TACE Combined with Lenvatinib-PD-1 Versus TACE Monotherapy as Conversion Therapy Before Liver Resection in Unresectable Hepatocellular Carcinoma: A Retrospective, Propensity Score Matching Study.

BACKGROUND: Transarterial chemoembolization (TACE) combined with Lenvatinib plus programmed death-1 inhibitor (PD-1 inhibitor) is recommended for unresectable hepatocellular carcinoma (uHCC), and it h…

Thérapies de Conversion
Lu, C., Liu, R., Zhang, Y., Luo, J., Luo, C., Jiang, Z., Huang, M., Qiu, C., & Chen, J. (2025). TACE Combined with Lenvatinib-PD-1 Versus TACE Monotherapy as Conversion Therapy Before Liver Resection in Unresectable Hepatocellular Carcinoma: A Retrospective, Propensity Score Matching Study.. J Hepatocell Carcinoma, 12, 1527-1540. https://doi.org/10.2147/JHC.S517855
01/01/2025 Lire →

Conversion therapy with TACE, TKIs, and ICIs for unresectable BCLC stage B and C hepatocellular carcinoma.

BACKGROUND AND AIMS: Most Hepatocellular carcinoma (HCC) diagnoses occur at advanced stages precluding radical surgical resections. Conversion therapy offers a viable chance for patients with unresect…

Thérapies de Conversion
Wang, Z., Zhang, C., Yin, J., & Li, N. (2025). Conversion therapy with TACE, TKIs, and ICIs for unresectable BCLC stage B and C hepatocellular carcinoma.. Front Immunol, 16, 1451965. https://doi.org/10.3389/fimmu.2025.1451965
01/01/2025 Lire →

Local-region treatment comparison following conversion therapy of hepatocellular carcinoma: a period and age-dependent analysis.

BACKGROUND: Transarterial chemoembolization (TACE) is a potential conversion therapeutic strategy for unresectable hepatocellular carcinoma (uHCC). However, therapeutic options following conversion th…

Thérapies de Conversion
Hu, J., Zhao, S., Zuo, M., Li, C. H., Yao, W., Yang, X., Xing, W., & Song, P. (2025). Local-region treatment comparison following conversion therapy of hepatocellular carcinoma: a period and age-dependent analysis.. Ther Adv Med Oncol, 17, 17588359251316665. https://doi.org/10.1177/17588359251316665
01/01/2025 Lire →

Conversion Therapy for Stage IV Gastric Cancer: Report From the Expert Consensus Meeting at KINGCA WEEK 2024.

Conversion therapy is a treatment strategy that shifts from palliative systemic therapy to curative surgical treatment for primary and/or metastatic stage IV gastric cancer (GC). To address its clinic…

Thérapies de Conversion
Kim, T. H., Uyama, I., Rha, S. Y., Bencivenga, M., An, J., Wyrwicz, L., Koo, D. H., van, H. i. l. l. e. g. e. r. s. b. e. r. g. . R., Lee, K. W., Li, G., Yoshikawa, T., Badgwell, B., Lorenzen, S., Kim, I. H., Lee, I. S., Han, H. S., & Hoon, H. (2025). Conversion Therapy for Stage IV Gastric Cancer: Report From the Expert Consensus Meeting at KINGCA WEEK 2024.. J Gastric Cancer, 25(1), 133-152. https://doi.org/10.5230/jgc.2025.25.e9
01/01/2025 Lire →